Logo image of TXMD

THERAPEUTICSMD INC (TXMD) Stock Fundamental Analysis

NASDAQ:TXMD - Nasdaq - US88338N2062 - Common Stock - Currency: USD

1.2  +0.06 (+5.26%)

After market: 1.2 0 (0%)

Fundamental Rating

3

Taking everything into account, TXMD scores 3 out of 10 in our fundamental rating. TXMD was compared to 194 industry peers in the Pharmaceuticals industry. While TXMD seems to be doing ok healthwise, there are quite some concerns on its profitability. TXMD has a valuation in line with the averages, but it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year TXMD has reported negative net income.
TXMD had a positive operating cash flow in the past year.
In the past 5 years TXMD reported 4 times negative net income.
In the past 5 years TXMD reported 4 times negative operating cash flow.
TXMD Yearly Net Income VS EBIT VS OCF VS FCFTXMD Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M

1.2 Ratios

TXMD has a Return On Assets of -5.49%. This is in the better half of the industry: TXMD outperforms 74.23% of its industry peers.
Looking at the Return On Equity, with a value of -7.85%, TXMD is in the better half of the industry, outperforming 78.35% of the companies in the same industry.
Industry RankSector Rank
ROA -5.49%
ROE -7.85%
ROIC N/A
ROA(3y)31.47%
ROA(5y)-21.67%
ROE(3y)92.01%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
TXMD Yearly ROA, ROE, ROICTXMD Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -500 -1K -1.5K

1.3 Margins

TXMD does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
TXMD Yearly Profit, Operating, Gross MarginsTXMD Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -2K -4K -6K

More info and screens

6

2. Health

2.1 Basic Checks

TXMD does not have a ROIC to compare to the WACC, probably because it is not profitable.
TXMD has about the same amout of shares outstanding than it did 1 year ago.
TXMD has more shares outstanding than it did 5 years ago.
There is no outstanding debt for TXMD. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
TXMD Yearly Shares OutstandingTXMD Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M
TXMD Yearly Total Debt VS Total AssetsTXMD Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

2.2 Solvency

Based on the Altman-Z score of -34.16, we must say that TXMD is in the distress zone and has some risk of bankruptcy.
TXMD has a worse Altman-Z score (-34.16) than 86.60% of its industry peers.
TXMD has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z -34.16
ROIC/WACCN/A
WACC10.04%
TXMD Yearly LT Debt VS Equity VS FCFTXMD Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M

2.3 Liquidity

A Current Ratio of 2.64 indicates that TXMD has no problem at all paying its short term obligations.
TXMD has a Current ratio of 2.64. This is comparable to the rest of the industry: TXMD outperforms 45.36% of its industry peers.
A Quick Ratio of 2.64 indicates that TXMD has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 2.64, TXMD is in line with its industry, outperforming 50.00% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 2.64
Quick Ratio 2.64
TXMD Yearly Current Assets VS Current LiabilitesTXMD Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

More info and screens

3

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 73.12% over the past year.
Looking at the last year, TXMD shows a very strong growth in Revenue. The Revenue has grown by 52.78%.
The Revenue for TXMD have been decreasing by -48.72% on average. This is quite bad
EPS 1Y (TTM)73.12%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%21.51%
Revenue 1Y (TTM)52.78%
Revenue growth 3Y-11.84%
Revenue growth 5Y-48.72%
Sales Q2Q%25.56%

3.2 Future

TXMD is expected to show a decrease in Earnings Per Share. In the coming years, the EPS will decrease by -8.87% yearly.
Based on estimates for the next years, TXMD will show a small growth in Revenue. The Revenue will grow by 1.92% on average per year.
EPS Next Y0%
EPS Next 2Y-30.31%
EPS Next 3Y-18.42%
EPS Next 5Y-8.87%
Revenue Next Year1.11%
Revenue Next 2Y1.65%
Revenue Next 3Y1.82%
Revenue Next 5Y1.92%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
TXMD Yearly Revenue VS EstimatesTXMD Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 20M 40M 60M 80M 100M
TXMD Yearly EPS VS EstimatesTXMD Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 10 -10 -20 -30

More info and screens

4

4. Valuation

4.1 Price/Earnings Ratio

TXMD reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
TXMD is valuated cheaply with a Price/Forward Earnings ratio of 6.92.
Based on the Price/Forward Earnings ratio, TXMD is valued cheaply inside the industry as 92.27% of the companies are valued more expensively.
TXMD is valuated cheaply when we compare the Price/Forward Earnings ratio to 37.36, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE N/A
Fwd PE 6.92
TXMD Price Earnings VS Forward Price EarningsTXMD Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Compared to the rest of the industry, the Price/Free Cash Flow ratio of TXMD indicates a rather cheap valuation: TXMD is cheaper than 93.30% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF 9.87
EV/EBITDA N/A
TXMD Per share dataTXMD EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 1 1.5 2

4.3 Compensation for Growth

TXMD's earnings are expected to decrease with -18.42% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-30.31%
EPS Next 3Y-18.42%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for TXMD!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

THERAPEUTICSMD INC

NASDAQ:TXMD (7/23/2025, 7:24:25 PM)

After market: 1.2 0 (0%)

1.2

+0.06 (+5.26%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)05-08 2025-05-08
Earnings (Next)08-11 2025-08-11
Inst Owners44.06%
Inst Owner Change0%
Ins Owners1.55%
Ins Owner Change0.18%
Market Cap13.88M
Analysts43.33
Price TargetN/A
Short Float %0.2%
Short Ratio0.45
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 6.92
P/S 7.54
P/FCF 9.87
P/OCF 9.87
P/B 0.52
P/tB 0.61
EV/EBITDA N/A
EPS(TTM)-0.19
EYN/A
EPS(NY)0.17
Fwd EY14.45%
FCF(TTM)0.12
FCFY10.13%
OCF(TTM)0.12
OCFY10.13%
SpS0.16
BVpS2.31
TBVpS1.95
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -5.49%
ROE -7.85%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM 76.43%
ROA(3y)31.47%
ROA(5y)-21.67%
ROE(3y)92.01%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score7
Asset Turnover0.05
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.64
Quick Ratio 2.64
Altman-Z -34.16
F-Score7
WACC10.04%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)73.12%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%21.51%
EPS Next Y0%
EPS Next 2Y-30.31%
EPS Next 3Y-18.42%
EPS Next 5Y-8.87%
Revenue 1Y (TTM)52.78%
Revenue growth 3Y-11.84%
Revenue growth 5Y-48.72%
Sales Q2Q%25.56%
Revenue Next Year1.11%
Revenue Next 2Y1.65%
Revenue Next 3Y1.82%
Revenue Next 5Y1.92%
EBIT growth 1Y55.2%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y117.86%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y118.2%
OCF growth 3YN/A
OCF growth 5YN/A